Sensulin

About:

Sensulin is a diabetes drug discovery company developing a once-a-day glucose-responsive insulin.

Twitter/X: sensulin

Top Investors: Propel(X), National Science Foundation, AngelMD, MassChallenge, Cortado Ventures

Description:

Sensulin, LLC is developing a true once-a-day glucose-responsive insulin, that may mimic a healthy human pancreas. Sensulin may eliminate the need for basal & prandial insulin, offer a substantial improvement in the standard of care, and most importantly, give those with diabetes a chance at a normal life.

Total Funding Amount:

$3.28M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Oklahoma City, Oklahoma, United States

Founded Date:

2011-08-09

Contact Email:

info(AT)sensulin.com

Founders:

Ananth Annapragada, Chris A. Rhodes, Daniel M. Bradbury, Mike Moradi

Number of Employees:

1-10

Last Funding Date:

2021-10-25

IPO Status:

Private

Industries: